Back to top

Arcus Biosciences price target raised to $29 from $25 at BofA

BofA raised the firm’s price target on Arcus Biosciences (RCUS) to $29 from $25 and keeps a Neutral rating on the shares. While early data support ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcus Biosciences, Inc. (RCUS)